American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(65), 2021
DOI: 10.1128/aac.02490-20
Full text: Unavailable
The high interindividual variability in the pharmacokinetics (PK) of linezolid has been described, which results in an unacceptably high proportion of patients with either suboptimal or potentially toxic concentrations following the administration of a fixed regimen. The aim of this study was to develop a population pharmacokinetic model of linezolid and use this to build and validate alogorithms for individualized dosing.